|Bid||3,495.00 x N/A|
|Ask||3,825.00 x N/A|
|Day's Range||3,487.00 - 3,500.00|
|52 Week Range||202.00 - 4,850.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Eli Lilly and Company (NYSE: LLY) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo® (selpercatinib) demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal (GI) malignancies. The data were presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021.
GlaxoSmithKline (NYSE: GSK), Vir Biotechnology (NASDAQ: VIR), and Eli Lilly (NYSE: LLY) recently reported positive results from a phase 2 study evaluating a combination of Lilly's bamlanivimab with Vir's and Glaxo's VIR-7831 in treating COVID-19. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli examine those results and discuss which of the three stocks is likely to be the biggest winner going forward.
Eli Lilly And Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) have reported results from the COV-BARRIER Phase 3 study evaluating baricitinib plus standard of care (SoC) versus placebo plus SoC in hospitalized COVID-19 patients. The trial did not meet statistical significance on the primary endpoint of the proportion of participants progressing to non-invasive ventilation or death by Day 28. Baricitinib-treated patients were 2.7% less likely than those receiving standard of care to progress to ventilation (non-invasive or mechanical) or death. Treatment with baricitinib in addition to SoC (which included 79% receiving corticosteroids and 19% receiving remdesivir, with some receiving both) resulted in a significant reduction in death from any cause by 38%. A numerical reduction in mortality was observed for all baseline severity subgroups of baricitinib-treated patients. It was most pronounced for patients receiving non-invasive mechanical ventilation at baseline (17.5% versus 29.4% for baricitinib plus SoC versus SoC. The frequency of adverse events was generally similar in the baricitinib and placebo groups. Severe infections and venous thromboembolism occurred in 8.5% and 2.7% of patients treated with baricitinib, respectively, versus 9.8 % and 2.5% on placebo. Lilly intends to publish detailed results of this study in a peer-reviewed journal in the coming months. The company will share the data from the study with regulatory authorities in the U.S., European Union, and other geographies to evaluate the next steps for baricitinib in hospitalized COVID-19 patients. Yesterday, the FDA extended the review period for baricitinib in atopic dermatitis by three months. Price Action: LLY shares are up 0.3% at $182.8 in premarket trading on the last check Thursday, while INCY shares closed 2.2% lower at $81.38 on Wednesday. See more from BenzingaClick here for options trades from BenzingaFortress Biotech's Partner Firm Expands Footprint In Dermatology With Qbrexza AcquisitionIncyte's Pemazyre Wins European Approval For Bile Duct Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.